Back to discover
Drug

Zinc

Approved · EMA
Emerging researchLate-stage developmentCooling momentum

Also known as Zinc, elemental, Zincum metallicum, Zn, Zn - Zinc.

18
Research papers
4
Active clinical trials
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

The Astrocytic Zinc Transporter ZIP12 Is a Synaptic Protein That Contributes to Synaptic Zinc Levels in the Mouse Auditory Cortex.

Research2025-03-26The Journal of neuroscience : the official journal of the Society for Neuroscience

Cell-type-specific enhancement of deviance detection by synaptic zinc in the mouse auditory cortex.

Research2024-09-23Proceedings of the National Academy of Sciences of the United States of America

Effects of a Supplementation With Zinc and Myo-inositol in Paediatric Obesity

Clinical trial2024-03-10Completed · ClinicalTrials.gov

Approval: Wilzin (EMA)

Regulatory2004-10-12EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Zinc
Aliases & brands
Zinc, elementalZincum metallicumZnZn - Zinc
RxNorm CUI
11416
ChEMBL ID
CHEMBL1201279
UNII
J41CSQ7QDS
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2004-10-12
Latest approval
2004-10-12
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2004-10-12Approval
Approval: Wilzin (EMA)

Indication: Treatment of Wilson's disease.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

48 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
48
registered trials across all phases
LATEST COMPLETION 2024
4
Active studies
4
Recruiting
38
Late-stage (III+)
33
Completed
11
Discontinued
PHASE DISTRIBUTIONn = 48
Phase 12Phase 1 / 22Phase 26Phase 2 / 32Phase 317Phase 411Phase N / A8

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

18 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20012025
Most influential
Recent papers

The Astrocytic Zinc Transporter ZIP12 Is a Synaptic Protein That Contributes to Synaptic Zinc Levels in the Mouse Auditory Cortex.

The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025 · 2 cites

Cell-type-specific enhancement of deviance detection by synaptic zinc in the mouse auditory cortex.

Proceedings of the National Academy of Sciences of the United States of America · 2024 · 8 cites

Zinc: From Biological Functions to Therapeutic Potential.

International journal of molecular sciences · 2023 · 129 cites

Common and Trace Metals in Alzheimer's and Parkinson's Diseases.

International journal of molecular sciences · 2023 · 58 cites
Major research themes8
Zinc4Auditory Cortex3Selenium3Synapses3Trace Elements3Dietary Supplements2Alzheimer Disease1Astrocytes1
Journals, researchers & institutions
Top journals
  • International journal of molecular sciences3
  • Frontiers in endocrinology2
  • Nutrients2
  • Archives of ophthalmology (Chicago, Ill. : 1960)1
  • Cell reports1
  • Chemical reviews1
Leading researchers
  • Anderson CT3
  • Bender PTR3
  • Mendelson BZ3
  • Manning A2
  • McCollum M2
  • Alterio V1
  • Ayton S1
  • Bainer K1
Leading institutions
free-text, unnormalised
  • Rockefeller Neuroscience Institute3
  • "Apollonia" University of Iasi1
  • "Grigore T. Popa" University of Medicine and Pharmacy1
  • Center for Innovative Biomedicine and Biotechnology (CIBB)1
  • Centre for Human Psychopharmacology1
  • Centro Hospitalar e Universitário de Coimbra (CHUC)1

Related diseases

2 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Related drugs

7 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across 9 of the same disease areas as Zinc in the shared literature.

9 shared diseases2 shared papers

Studied across 6 of the same disease areas as Zinc in the shared literature.

6 shared diseases1 shared paper

Studied across 3 of the same disease areas as Zinc in the shared literature.

3 shared diseases3 shared papers

Studied across 4 of the same disease areas as Zinc in the shared literature.

4 shared diseases1 shared paper

Studied across 3 of the same disease areas as Zinc in the shared literature.

3 shared diseases1 shared paper

Studied across 2 of the same disease areas as Zinc in the shared literature.

2 shared diseases1 shared paper

Frequently co-studied with Zinc in the research literature.

1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.